Carlino Matteo S

Cytowane przez

	Wszystkie	Od 2020
Cytowania	55643	39468
h-indeks	81	71
i10-indeks	232	212

8000

4000

2000

6000

201420152016201720182019202020212022202320242025172 701 2317 3304 3982 4984 6835 7880 7586 7763 7957 1342

Dostęp publiczny

Wyświetl wszystko

137 artykułów

11 artykułów

dostępne

niedostępne

Objęte finansowaniem

Współautorzy

Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore HospitalZweryfikowany adres z sydney.edu.au
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Royal North Shore HospitalZweryfikowany adres z sydney.edu.au
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Royal Prince Alfred HospitalZweryfikowany adres z sswahs.nsw.gov.au
Antoni RibasUCLAZweryfikowany adres z mednet.ucla.edu
Serigne LoMelanoma Institute Australia, The University of SydneyZweryfikowany adres z melanoma.org.au
James LarkinRoyal Marsden Hospital / Institute of Cancer Research, London, UKZweryfikowany adres z rmh.nhs.uk
Blank cNetherlands Cancer InstituteZweryfikowany adres z nki.nl
Robyn SawMelanoma Institute AustraliaZweryfikowany adres z melanoma.org.au
John F ThompsonMelanoma Institute AustraliaZweryfikowany adres z melanoma.org.au
Adil DaudProfessor of Medicine, University of California, San FranciscoZweryfikowany adres z ucsf.edu
Victoria AtkinsonUniversity of Queensland, Princess Alexandra Hospital, Gallipoli Medical Research FoundationZweryfikowany adres z health.qld.gov.au
James S WilmottMelanoma Institute Australia, The University of SydneyZweryfikowany adres z sydney.edu.au
Paolo A. AsciertoIstituto Nazionale Tumori Fondazione "G. Pascale", Napoli, ItalyZweryfikowany adres z istitutotumori.na.it
Ryan SullivanMassachusetts General HospitalZweryfikowany adres z mgh.harvard.edu
Ben KongPrince of Wales Hospital, NHMRC Clinical Trials Centre, SPHERE Cancer Clinical Academics Group UNSWZweryfikowany adres z sydney.edu.au
Adnan NagrialUniversity of SydneyZweryfikowany adres z health.nsw.gov.au
Pablo Fernandez-PeñasThe University of Sydney, Dermatology, Westmead HospitalZweryfikowany adres z sydney.edu.au
Lauren E. Haydu, PhD MPHMayo ClinicZweryfikowany adres z mayo.edu
Peter HerseyZweryfikowany adres z sydney.edu.au
Therese BeckerCirculating Tumour Cell Program LeaderZweryfikowany adres z unsw.edu.au

Obserwuj

Carlino Matteo S

Melanoma Institute Australia; Westmead Hospital

Zweryfikowany adres z sydney.edu.au - Strona główna

Melanoma


Tytuł Sortuj wg cytatów Sortuj wg roku Sortuj wg tytułu	Cytowane przez Cytowane przez	Rok
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015	8436	2015
Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015	6474	2015
Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017	3870	2017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019	3570	2019
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018	2344	2018
Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018	1974	2018
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015	1842	2015
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet 390 (10105), 1853-1862, 2017	1380	2017
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709-717, 2017	1168	2017
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019	1165	2019
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022	906	2022
Immune checkpoint inhibitors in melanoma MS Carlino, J Larkin, GV Long The Lancet 398 (10304), 1002-1014, 2021	873	2021
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017	858	2017
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double … GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ... The Lancet Oncology 20 (8), 1083-1097, 2019	786	2019
Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019	780	2019
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016	667	2016
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018	612	2018
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ... Clinical cancer research 20 (7), 1965-1977, 2014	598	2014
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma AM Menzies, LE Haydu, L Visintin, MS Carlino, JR Howle, JF Thompson, ... Clinical cancer research 18 (12), 3242-3249, 2012	567	2012
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022	434	2022

Nie można teraz wykonać tej operacji. Spróbuj ponownie później.

Prace 1–20

Cytowania rocznie

Powielone cytowania

Scalone cytowania

Dodaj współautorówWspółautorzy

Obserwuj

Cytowane przez

Współautorzy